| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Clever Leaves Holdings Inc. (NASDAQ:CLVR), has been granted Australian GMP certification for its facilities in Colombia by the Therapeutic Goods Administration (TGA).
The certification authorizes Clever Leaves to manufacture cannabis products for medical marijuana patients in Australia, the Colombia-based company announced on Wednesday.
The Australian GMP certification from the TGA safeguards against product contamination, variations in compound concentrations, mix-ups, incorrect labeling and other potential issues. The certification is a prerequisite for the manufacturing and commercialization of cannabis products in the Australian market.
See also: Meet The First Vertically Integrated Medicinal Cannabis Company Certified As Carbon-Neutral
“The awarding of Australian-GMP certification signifies a major milestone for Clever Leaves by further highlighting our commitment to producing high-quality and safe cannabis products in one of the fastest growing and largest medicinal cannabis markets globally," Andres Fajardo, Clever Leaves CEO said. "We will continue distributing through our partners, with whom we are already distributing finished cannabis products to patients in the country."
According to official data from the TGA, during the first half of 2023, some 325,000 new Australian patients began treatment. In 2022, the number of new patients was 320,000 for the full year. In 2021, there were 150,000.
Clever Leaves also holds GMP certifications from the European Union, Colombia and Brazil.
Clever Leaves' shares traded 0.96% lower at $2.06 per share during the pre-market session on Wednesday morning.
Missed the first wave of cannabis investments? Don't make that mistake again.
Experts believe cannabis stocks have found their floor and are now poised for unprecedented growth.
Join Benzinga PotProfits. Our in-house canna stock expert, Michael Berger, is on a mission to uncover the most promising cannabis stocks poised for growth, even in a dull market. He leaves no bud unturned to bring you the juiciest potential double-digit opportunities!
Just this year, the PotProfits portfolio has seen smoking-hot gains like:
But here's the kicker: Michael is about to release his next potential winners, and he's chomping at the bit to share these ticker symbols with you ASAP.
Don't miss out on the green rush!
Posted In: CLVR
